© 2000 American Heart Association, Inc.
Thrombosis |
Reversible Regulation of Tissue Factor–Induced Coagulation by Glycosyl Phosphatidylinositol–Anchored Tissue Factor Pathway Inhibitor
From the Departments of Immunology (B.M.M., W.R.), Molecular and Experimental Medicine (M.J.H.), and Vascular Biology (M.J.H., B.M.M., W.R.), The Scripps Research Institute, La Jolla, Calif; Deutsches Herzzentrum (I.O.), Munich, Germany; the Department of Pathology (Y.M.) and the Kihara Institute for Biological Research (K.M.), Yokohama City University, Yokohama, Japan; and the Department of Biochemistry (L.V.M.R.), University of Texas Health Center at Tyler, Tyler, Tex.
Correspondence to Dr Wolfram Ruf, Department of Immunology, IMM-17, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037. E-mail ruf{at}scripps.edu
Abstract—Endothelial and tumor cells synthesize tissue factor pathway inhibitor (TFPI-1), which regulates tissue factor (TF) function by TF · VIIa · Xa · TFPI-1 quaternary complex formation (where VIIa and Xa are coagulation factors) and by translocation of these complexes into glycosphingolipid-rich microdomains of the cell membrane. Recombinant TFPI-1 added exogenously to cells is targeted to a degradation pathway. This study analyzes whether quaternary complex formation with endogenous TFPI-1 results also in internalization and degradation. We demonstrate that endogenous TFPI-1 and recombinant TFPI-1 differ in their distribution on the cell surface. Recombinant TFPI-1 is found in phospholipid- and glycosphingolipid-rich membrane domains, whereas endogenous TFPI-1 preferentially localizes to glycosphingolipid-rich microdomains. On quaternary complex formation, endogenous TFPI-1 remains protease sensitive and accessible for antibodies on intact cells, demonstrating that it is not appreciably internalized. Rather, regulation of TF by TFPI-1 is restored within 12 hours, consistent with dissociation of quaternary complexes on the cell surface. Endogenous TFPI-1 can be released from the cell surface by phospholipase treatment, indicating that TFPI-1 either is a glycosyl phosphatidylinositol (GPI)-anchored protein or binds to a GPI-linked receptor. We demonstrate that expression of a recombinant GPI-anchored form of TFPI-1 targets TF · VIIa complexes to glycosphingolipid-rich membrane fractions. Thus, GPI anchoring of TFPI-1 is sufficient for regulation of TF · VIIa complex function by a pathway of reversible inhibition rather than internalization and degradation.
Key Words: coagulation cascade • Kunitz-type inhibitors • cell surface proteoglycans • glycosphingolipid-rich microdomains
This article has been cited by other articles:
 |
|
 |
|
  S. Pan, T. A. White, T. A. Witt, A. Chiriac, C. S. Mueske, and R. D. Simari Vascular-Directed Tissue Factor Pathway Inhibitor Overexpression Regulates Plasma Cholesterol and Reduces Atherosclerotic Plaque Development Circ. Res., September 25, 2009; 105(7): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Tanaka, N. S. Key, and J. H. Levy Blood Coagulation: Hemostasis and Thrombin Regulation Anesth. Analg., May 1, 2009; 108(5): 1433 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E.R. Ellery, K. Hardy, R. Oostryck, and M. J. Adams Further Insight Into the Heparin-Releasable and Glycosylphosphatidylinositol-Lipid-- Anchored Forms of Tissue Factor Pathway Inhibitor Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 267 - 278. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Schouten, W. J. Wiersinga, M. Levi, and T. van der Poll Inflammation, endothelium, and coagulation in sepsis J. Leukoc. Biol., March 1, 2008; 83(3): 536 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T.B. Crawley and D. A. Lane The Haemostatic Role of Tissue Factor Pathway Inhibitor Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lupu, X. Hu, and F. Lupu Caveolin-1 Enhances Tissue Factor Pathway Inhibitor Exposure and Function on the Cell Surface J. Biol. Chem., June 10, 2005; 280(23): 22308 - 22317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-H. Chen, C. P. Vicente, L. He, D. M. Tollefsen, and T.-C. Wun Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants Blood, May 15, 2005; 105(10): 3902 - 3909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ahamed, M. Belting, and W. Ruf Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1 Blood, March 15, 2005; 105(6): 2384 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Piro and G. J. Broze Jr Role for the Kunitz-3 Domain of Tissue Factor Pathway Inhibitor-{alpha} in Cell Surface Binding Circulation, December 7, 2004; 110(23): 3567 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Neaud, J. G. Duplantier, C. Mazzocco, W. Kisiel, and J. Rosenbaum Thrombin Up-regulates Tissue Factor Pathway Inhibitor-2 Synthesis through a Cyclooxygenase-2-dependent, Epidermal Growth Factor Receptor-independent Mechanism J. Biol. Chem., February 13, 2004; 279(7): 5200 - 5206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ruf, E. A. Seftor, R. J. Petrovan, R. M. Weiss, L. M. Gruman, N. V. Margaryan, R. E. B. Seftor, Y. Miyagi, and M. J. C. Hendrix Differential Role of Tissue Factor Pathway Inhibitors 1 and 2 in Melanoma Vasculogenic Mimicry Cancer Res., September 1, 2003; 63(17): 5381 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, O. Piro, L. Lu, and G. J. Broze Jr Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway Inhibitor Circulation, August 5, 2003; 108(5): 623 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Mast, N. Acharya, M. J. Malecha, C. L. Hall, and D. J. Dietzen Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 2099 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ott, V. Malcouvier, A. Schomig, and F.-J. Neumann Proteolysis of Tissue Factor Pathway Inhibitor-1 by Thrombolysis in Acute Myocardial Infarction Circulation, January 22, 2002; 105(3): 279 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ott, M. Andrassy, D. Zieglgansberger, S. Geith, A. Schomig, and F.-J. Neumann Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1 Blood, June 15, 2001; 97(12): 3721 - 3726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Mast, J. E. Stadanlick, J. M. Lockett, D. J. Dietzen, K. A. Hasty, and C. L. Hall Tissue Factor Pathway Inhibitor Binds to Platelet Thrombospondin-1 J. Biol. Chem., October 6, 2000; 275(41): 31715 - 31721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|